Biotech Values

[Laloo77]

DD, I am bullish based on the potential the current IPCI pipeline means for the Company. The current revenues for Focalin are their for you to see and this represents a couple of quarters of sales. We all know that the current healthcare trend is towards generics from an industry perspective.

However, the one issue which I think would be a game changer for IPCI is the Rexista Abuse resistant Oxycondone. This looks to me as the wave of the future. With so much concern around the dependency and abuse of pain killers, If IPCI is successful in developing Rexista to market. Watch out.

Overall its hard to find a biotech company out there that is projected to be profitable with up to 8 ANDA's in the pipeline and a couple of in house drugs under development which currently has a market cap under $100 million. It is only a matter of time.